
Zydus Cadila has received final approval from the US health regulator to market Carbidopa tablets, used for treating symptoms of Parkinson’s disease. Parkinson’s symptoms include shakiness, stiffness and difficulty in moving.
Zydus Cadila has received the final approval from the USFDA to market Carbidopa tablets (25 mg), the company said in a BSE filing.
The approved product will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
0 comment(s) on Zydus Cadila gets USFDA nod for Carbidopa tablets